HIV integrase inhibitors: a new era in the treatment of HIV. (Q30956943)

27 June 2017

1 reference

title

HIV integrase inhibitors: a new era in the treatment of HIV. (English)

1 reference

27 June 2017

Ana Milinkovic

3

0 references

Gary Whitlock

object named as

Gary Whitlock

series ordinal

2

1 reference

ORCID Public Data File 2021

author name string

Jose Luis Blanco

series ordinal

1

1 reference

27 June 2017

Graeme Moyle

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

Expert Opinion on Pharmacotherapy

27 June 2017

published in

1 reference

27 June 2017

volume

16

1 reference

27 June 2017

issue

9

1 reference

27 June 2017

page(s)

1313-1324

1 reference

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Dolutegravir: an exciting new kid on the block

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

The problem of renal function monitoring in patients treated with the novel antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Body composition changes after switching from protease inhibitors to raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 w

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1044436

10.1517/14656566.2015.1044436

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference